Skip to main content

Table 3 Improved OA Pain Intensity and Patient's and Physician's Global Assessments of Disease Activity (ITT Population)

From: Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: A randomised controlled trial in patients with osteoarthritis

  Lumiracoxib 100 mg o.d. (n = 755) Lumiracoxib 100 mg b.i.d. (n = 1,519) Celecoxib 200 mg o.d. (n = 758)
Patient's target joint pain intensity assessment    
   Changes in scores from baseline to study endpoint, n (%)    
Improvement 382 (50.6) 795 (52.3) 406 (53.6)
No change 269 (35.6) 566 (37.3) 265 (35.0)
Worsened 104 (13.8) 158 (10.4) 87 (11.5)
   Overall measure of efficacy, least squares mean 2.78 2.72 2.77
Patient's global assessment of disease activity    
   Changes in scores from baseline to study endpoint, n (%)    
Improvement 368 (48.7) 768 (50.6) 373 (49.2)
No change 265 (35.1) 534 (35.2) 269 (35.5)
Worsened 122 (16.2) 216 (14.2) 116 (15.3)
   Overall measure of efficacy, least squares mean 2.61 2.54 2.60
Physician's global assessment of disease activity    
   Changes in scores from baseline to study endpoint, n (%)    
Improvement 411 (54.5) 888 (58.5) 425 (56.2)
No change 244 (32.4) 463 (30.5) 232 (30.7)
Worsened 99 (13.1) 167 (11.0) 99 (13.1)
   Overall measure of efficacy, least squares mean 2.55 2.45* 2.52
  1. o.d. = once daily; b.i.d. = twice daily; ITT = intention-to-treat; patients with missing baseline values were not included; Overall measure of efficacy defined as the weighted average of post-baseline scores using the last observation carried forward technique for missing values and time since previous visit as weight (lower scores represent better responses); *p < 0.05 vs lumiracoxib 100 mg o.d. and celecoxib 200 mg o.d.